Subscribe to Search results

Alter et al showed that after excluding commercial and Hepatitis B antigen positive donors, post-transfusion hepatitis remained.

Published on:

Dr Rainsford identified that the hepatitis of a boy under his care at Treloar's was almost certainly caused by plasma.

Published on:

There was a hepatitis outbreak at Treloar's in 1975.

Published on:

Dr Arblaster asked a parent of a Treloar's student to reconsider their decision to withdraw consent for him to be treated with "new material".

Published on:

The results of a third prophylaxis trial undertaken at Treloar's were reported to UKHCDO Directors.

Published on:

A trial was carried out at Treloar's aimed to see if prophylaxis would improve the radiological appearance of joints and "more particularly have any influence on haemophilic cysts." It was stated that there could be a significant lessening in the number of bleeds, but to achieve this, it would require amounts of concentrate which were simply unavailable in such quantities.

Published on:

Andrew Quinn, a pupil at Treloar's, was selected to receive Factor 8 prophylactically for a year. He was never advised that there were any risks attached to receiving Factor 8.

Published on:

From 1970 to 1973, Dr Rainsford studied the incidence of serum hepatitis. The aim was to see if there was any pattern to the way in which antibodies and antigens to serum hepatitis correlated with clinical illness, the frequency of transfusion and the presence of antigens in the blood products with which they were being treated.

Published on:

It was acknowledged that recent research had shown that viruses other than Hepatitis A and B may have caused significant amount of post-transfusion hepatitis.

Published on:

Hemofil was given to one child as part of the study; he did not bleed frequently and so needed only limited treatment, but went on to develop acute hepatitis.

Published on:

Dr Kirk wrote to parents of a student at Treloar's to inform them their son had been "selected to receive only Kryobulin when he requires transfusing. By limiting him to this type of factor VIII containing material it will be easier to trace the source should he contract hepatitis."

Published on:

A letter about a Treloar's pupil written to his home clinician showed that there had been no advance discussion about the research on him.

Published on:

Dr Kirk proposed to restrict patients to either commercial concentrates as a group or cryoprecipitate or Lister Concentrate as part of the next stage of a hepatitis study.

Published on:

Dr Craske from the Public Health Laboratory Service encouraged further study of hepatitis associated with the use of commercial Factor 8.

Published on:

Dr Craske encouraged further research and applied for a research grant on hepatitis associated with the use of commercial Factor 8.

Published on:

There was a trial to see which of three dosage regimes addressed bleeds into knee, elbow and ankle joints most effectively. This involved pupils being given doses of 7, 14, or 28 units (per kilogram of their bodyweight), and was written up in The Lancet.

Published on:

A report of a trial stated that there was "growing evidence that chronic hepatitis was a not-uncommon consequence of transfusion", related to the total number of donors to whose blood a patient had been exposed.

Published on:

Dr Aronstam informed the Treloar's students about AIDs and said the risk was "very small".

Published on:

In late 1984, Treloar clinicians told pupils that HIV infections were an unavoidable accident.

Published on:

Gary Bennett, a student at Treloar's, was put on "long term prophylaxis" for which three different types of concentrate were used.

Published on: